论文部分内容阅读
BACKGROUND AND OBJECTIVE: To evaluate the effect of intraoperative intracamera l injection of 2%hydroxypropyl methylcellulose (HPMC) on anterior chamber depth and intraocular pressure (IOP) following trabeculectomy in eyes with uncontroll ed primary open-angle glaucoma in a prospective randomized manner. PATIENTS AND METHODS: Thirty consecutive eyes with primary open-angle glaucoma scheduled fo r trabeculectomy were randomized to conventional trabeculectomy without HPMC inj ection (group I; n=15) or to intracameral injection of 2%HPMC during trabeculec tomy (group II; n=15). All patients were observed serially on days 1, 3, 5, 7, a nd 14 and months 1, 3, and 6 postoperatively. The main outcome measure was resto ration of anterior chamber depth to preoperative level with IOP of less than 21m mHg with no additional antiglaucoma medication or surgery. RESULTS: The anterior chamber depth decreased from 2.5 ±0.53 to 1.5 ±0.94 mm on postoperative day 1 in group I and increased slightly from 2.4 ±0.43 to 2.5 ±0.36 mm on postopera tive day 1 in group II (P=.04). Overall, the IOP decreased to 5.0 ±2.8 mm Hg in group I (87%reduction) and 9.0 ±4.6 mm Hg in group II (70%reduction). Two ey es developed postoperative flat anterior chamber and related complications in gr oup I, whereas none of the eyes in group II developed such complications. CONCLU SIONS: Intracameral injection of 2%HPMC during trabeculectomy helps to maintain anterior chamber depth and reduces incidence of complications related to shallo w anterior chamber depth following trabeculectomy.
BACKGROUND AND OBJECTIVE: To evaluate the effect of intraoperative injection of 2% hydroxypropyl methylcellulose (HPMC) on anterior chamber depth and intraocular pressure (IOP) following trabeculectomy in eyes with uncontrolled ed primary open-angle glaucoma in a prospective randomized manner. PATIENTS AND METHODS: Thirty consecutive eyes with primary open-angle glaucoma scheduled fo r trabeculectomy were randomized to conventional trabeculectomy without HPMC inj ection (group I; n = 15) or to intracameral injection of 2% HPMC during trabeculec tomy (group II; n = 15). All patients were observed serially on days 1, 3, 5, 7, a nd 14 and months 1, 3, and 6 postoperatively. The main outcome measure was resto ration of anterior chamber depth to preoperative level with IOP of less than than 21 m mHg with no additional antiglaucoma medication or surgery. RESULTS: The anterior chamber depth decreased from 2.5 ± 0.53 to 1.5 ± 0.94 mm on postoperative day 1 in group I and highly slightly fro fro m 2.4 ± 0.43 to 2.5 ± 0.36 mm on postopera tive day 1 in group II (P = .04). Overall, the IOP decreased to 5.0 ± 2.8 mm Hg in group I (87% reduction) and 9.0 ± 4.6 mm Hg in group II (70% reduction). Two ey es developed postoperative flat anterior chamber and related complications in gr oup I, none none of the eyes in group II developed such complications. CONCLU SIONS: Intracameral injection of 2% HPMC during trabeculectomy helps to maintain anterior chamber depth and reduces incidence of complications related to shallo w anterior chamber depth following trabeculectomy.